Myriad Genetics Inc (MYGN) Stock Price, Quote & News

Company Profile

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 801 584 3600

Fax: 801 584 3640

Website: www.myriad.com

Address:

322 North 2200 West, Salt Lake City, United States

PeakedSeller Mar. 14 at 1:11 PM

$MYGN $EVH my two undervalued healthcare picks for 2026… EVH has a more ayssymmetric upside with higher risk on the debt side. Execution equals 300-500% gain in less than a year MYGN is just a safe double bagger with their new MRD launch (read the data, it’s amazing).

0 · Reply

PeakedSeller Mar. 13 at 2:13 PM

$MYGN at $4.75 is straight-up undervalued 🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥 CEO Samraat Raha just bought 40,000 shares near $5.00 + Director Louise Phanstiel loaded ~104k shares at $4.66–$4.80 — over $690K of real insider buying right after earnings! Trading at only 0.55x sales, 70% gross margins, clean balance sheet, and catalysts are firing: • Precise MRD already in commercial testing (launched March) • Prolaris AI launch Q2 • FirstGene full rollout H2 My target: $9–11 by year-end (100%+ upside). Insiders aren’t buying for fun — they’re seeing the bottom. Loading up. $MYGN #Biotech #InsiderBuying #PrecisionMedicine #CancerCare

0 · Reply

AZOZ Mar. 10 at 11:34 AM

$MYGN $TTEC $COTY Insider trading!

1 · Reply

CEOBuysDisclosures Mar. 10 at 1:05 AM

$MYGN CEO purchased 40,000 shares at $5.00 for a total of $199,844. Raha Samraat S. now owns 493,104 shares. https://ceo-buys.com

0 · Reply

OkieDokieTrader Mar. 4 at 5:01 PM

$MYGN I’d appreciate a follow. I make calls like this time and time again. BEFORE they move!

0 · Reply

OfficialStocktwitsUser Mar. 3 at 11:15 PM

$MYGN RSI: 54.51, MACD: -0.2251 Vol: 0.36, MA20: 4.79, MA50: 5.62 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

OkieDokieTrader Mar. 3 at 6:07 PM

$MYGN Blast off!

0 · Reply

WhyYouMat Feb. 27 at 10:59 PM

Interesting that CAPS is setting off an alert 👀 people don’t realize how low this float is. Any sort of buying & it’d be >$1 in a heartbeat. De-risking it from NASDAQ noncompliance would carry it further, just like what happened with $OPEN… 🧐 $BTOC $GITS $MRM $MYGN

1 · Reply

topstockalerts Feb. 27 at 10:45 PM

After Hours Top Gainers PT2 $MRM $BTOC $MYGN $GITS $CAPS

0 · Reply

Mor20 Feb. 26 at 4:23 PM

$MYGN 5$

0 · Reply

Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth

Feb 23, 2026, 10:54 PM EST - 20 days ago

Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript

Feb 23, 2026, 4:05 PM EST - 20 days ago

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Feb 19, 2026, 9:15 AM EST - 24 days ago

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

Feb 16, 2026, 4:15 PM EST - 27 days ago

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

Jan 14, 2026, 11:05 PM EST - 2 months ago

Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:30 AM EST - 2 months ago

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Jan 5, 2026, 4:15 PM EST - 2 months ago

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Nov 25, 2025, 4:15 PM EST - 3 months ago

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

Nov 11, 2025, 9:00 AM EST - 4 months ago

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Nov 5, 2025, 1:36 PM EST - 4 months ago

Myriad Genetics: Downgrading To "Hold" Rating On Break-Even Q3 Earnings

Nov 3, 2025, 11:56 PM EST - 4 months ago

Myriad Genetics, Inc. (MYGN) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 4:05 PM EST - 4 months ago

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

Oct 31, 2025, 9:05 AM EDT - 4 months ago

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

Oct 27, 2025, 4:15 PM EDT - 4 months ago

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

Oct 14, 2025, 8:00 AM EDT - 5 months ago

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

Oct 8, 2025, 5:21 PM EDT - 5 months ago

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

Sep 23, 2025, 8:01 AM EDT - 6 months ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SOPH

Sep 23, 2025, 8:00 AM EDT - 6 months ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SOPH

Sep 10, 2025, 11:06 AM EDT - 6 months ago

Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 7:00 PM EDT - 6 months ago

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

Sep 3, 2025, 4:30 PM EDT - 6 months ago

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

Aug 18, 2025, 8:30 AM EDT - 7 months ago

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

Aug 13, 2025, 8:00 AM EDT - 7 months ago

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

Aug 6, 2025, 5:51 PM EDT - 7 months ago

Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth

Aug 6, 2025, 4:14 AM EDT - 7 months ago

Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 7 months ago

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

Jun 3, 2025, 9:00 AM EDT - 10 months ago

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

May 27, 2025, 4:05 PM EDT - 10 months ago

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

May 27, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation

May 26, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect

May 25, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out

May 23, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation

May 21, 2025, 10:00 AM EDT - 10 months ago

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 20, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Investors to Connect

May 19, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Stockholders to Inquire about Securities Investigation

May 16, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Investors to Reach Out

May 15, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out

May 14, 2025, 4:45 PM EDT - 10 months ago

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

May 14, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Connect

PeakedSeller Mar. 14 at 1:11 PM

0 · Reply

PeakedSeller Mar. 13 at 2:13 PM

0 · Reply

AZOZ Mar. 10 at 11:34 AM

$MYGN $TTEC $COTY Insider trading!

1 · Reply

CEOBuysDisclosures Mar. 10 at 1:05 AM

$MYGN CEO purchased 40,000 shares at $5.00 for a total of $199,844. Raha Samraat S. now owns 493,104 shares. https://ceo-buys.com

0 · Reply

OkieDokieTrader Mar. 4 at 5:01 PM

$MYGN I’d appreciate a follow. I make calls like this time and time again. BEFORE they move!

0 · Reply

OfficialStocktwitsUser Mar. 3 at 11:15 PM

0 · Reply

OkieDokieTrader Mar. 3 at 6:07 PM

$MYGN Blast off!

0 · Reply

WhyYouMat Feb. 27 at 10:59 PM

1 · Reply

topstockalerts Feb. 27 at 10:45 PM

After Hours Top Gainers PT2 $MRM $BTOC $MYGN $GITS $CAPS

0 · Reply

Mor20 Feb. 26 at 4:23 PM

$MYGN 5$

0 · Reply

BillionerOfKing Feb. 25 at 10:28 PM

$MYGN Current Stock Price: $4.78 Contracts to trade: $5.0 MYGN Mar 20 2026 Call Entry: $0.20 Exit: $0.39 ROI: 97% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Mor20 Feb. 25 at 6:47 PM

$MYGN going to 5$

0 · Reply

StardustCrusader Feb. 24 at 2:35 PM

$MYGN Well there goes all my trading progress for the last two weeks...

0 · Reply

PSM_EmpowerTrading Feb. 24 at 2:26 PM

🌅 Watchlist part 2 ✅ $SILO low $0.30 support, if above $0.45, have potential to $0.60 / $0.70 ✅ $MYGN low $5 support, if above $5.50, have potential to $5.80 / $6 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support. 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance. ⏳⏳ $NVVE $MVST still in swing accumulation phase 🎯🎯 Goal is GR 🤑🤑 not GD 🥵🥵

0 · Reply

topstockalerts Feb. 24 at 1:49 PM

$MYGN Looking good!

0 · Reply

OpenOutcrier Feb. 24 at 1:47 PM

$MYGN (+19.9% pre) Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y https://ooc.bz/l/94406

0 · Reply

GSP Feb. 24 at 1:20 PM

Updated gapper list: $MYGN $VIR $GNPX $BNAI $LRMR

0 · Reply

ZacksResearch Feb. 24 at 1:15 PM

$MYGN jumps 21.7% post-earnings surprise — but is it sustainable? 🤔 💥 Q4 EPS of 4 cents surpassed Zacks Consensus Estimate by 350%, with revenues topping forecasts despite a slight decline. 📉 Yet, gross margins fell 168 bps, and mental health revenues took a hit due to UnitedHealthcare's policy change. See if the rally can continue here 👉 https://www.zacks.com/stock/news/2874045/mygn-stock-up-on-q4-earnings-and-revenue-beat-gross-margin-down?cid=sm-stocktwits-2-2874045-body-34798&ADID=SYND_STOCKTWITS_TWEET_2_2874045_BODY_34798

0 · Reply

GSP Feb. 24 at 1:11 PM

Gap play watch list for today (so far): $MYGN $VIR $GNPX $BNAI $LRMR

0 · Reply

topstockalerts Feb. 24 at 1:06 PM

$MYGN following closely 👀

0 · Reply

ZacksResearch Feb. 24 at 12:15 PM

$MYGN pops on a Q4 beat — but there’s a catch. The company topped both earnings and revenue expectations for Q4, yet gross margin moved lower — a mixed signal that smart investors shouldn’t ignore. ⚠️ Is this strength sustainable or margin pressure the real story? Full breakdown here 👉 https://www.zacks.com/stock/news/2874045/mygn-stock-up-on-q4-earnings-and-revenue-beat-gross-margin-down?cid=sm-stocktwits-2-2874045-teaser-34784&ADID=SYND_STOCKTWITS_TWEET_2_2874045_TEASER_34784

0 · Reply

char13 Feb. 24 at 11:09 AM

$MYGN could be good today

0 · Reply

Market Cap	435.75M
Revenue (ttm)	824.50M
Net Income (ttm)	-365.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-44.38%
Debt to Equity Ratio	0.33

Volume	1,723,800
Avg Vol	1,358,222
Day's Range	N/A - N/A
Shares Out	93.51M
Stochastic %K	5%
Beta	1.91
Analysts	Sell
Price Target	$7.78